Gilead Expands Access to Investigational Ebola Drug Through Voluntary Licensing
Gilead said it is expanding access to investigational obeldesivir for Ebola Bundibugyo virus disease through voluntary licensing.
Story updates
09:05:28 PM UTC
SquawkNews
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis (PEP) for Ebola Bundibugyo virus disease…
09:05:32 PM UTC
SquawkNews
Agreements Signed in Advance of Results from the Ebola Post-Exposure Prophylaxis Field Trial and P